Ranolazine Implantable Cardioverter-Defibrillator Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1012 participants.

Also called NCT01215253

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,012 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01215253
Other papers using this trial's data
  • Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial Journal of the American College of Cardiology, 2018-08-07 DOI, PubMed 30071993
  • Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial JACC. Clinical electrophysiology, 2022-06 DOI, PubMed 35738852, PMC9473303 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01215253. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2017-02-28 (actual). Results posted on 2018-06-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ranolazine Implantable Cardioverter-Defibrillator Trial
Acronym
RAID
Condition
Ischemic Cardiomyopathy
Condition
Nonischemic Cardiomyopathy
Condition
Heart Failure
Intervention (Drug)
Ranolazine
Lead sponsor
University of Rochester (class: other)

Record details

Record id
cardio:ct-nct01215253
Content hash
f1c5f24d8da53fa097387afedbb13364be7015adbc244e2cf783e5835b9d8a03